Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

The estrogen receptor (ER) drives the growth of most luminal breast cancers and is the primary target of endocrine therapy. Although ER blockade with drugs such as tamoxifen is very effective, a major clinical limitation is the development of endocrine resistance especially in the setting of metasta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proc Natl Acad Sci U S A
Hauptverfasser: Jeselsohn, Rinath, Cornwell, MacIntosh, Pun, Matthew, Buchwalter, Gilles, Nguyen, Mai, Bango, Clyde, Huang, Ying, Kuang, Yanan, Paweletz, Cloud, Fu, Xiaoyong, Nardone, Agostina, De Angelis, Carmine, Detre, Simone, Dodson, Andrew, Mohammed, Hisham, Carroll, Jason S., Bowden, Michaela, Rao, Prakash, Long, Henry W., Li, Fugen, Dowsett, Mitchell, Schiff, Rachel, Brown, Myles
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2017
Schlagworte:
PNAS Plus
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5465894/
https://ncbi.nlm.nih.gov/pubmed/28507152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1620993114
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge